Back to previous section

AstraZenca shares fall as US advisory panel votes against breast cancer drug

AstraZeneca shares fell on Friday after its experimental breast cancer treatment was given the thumbs down by an an advisory panel for the US Food and Drug Administration.

AstraZeneca

Source: Sharecast

The FDA's Oncologic Drugs Advisory Committee (ODAC) voted three to six against recommending camizestrant, which is being developed for a type of breast cancer in which tumours have a specific mutation, citing concerns about study design rather than safety or efficacy itself.

The company is looking for FDA approval to use the drug as a first-line treatment for patients with hormone receptor-positive, HER2-negative advanced breast cancer whose tumours have an emergent ESR1 mutation.

"The FDA is not bound by the committee's guidance but takes its advice into consideration. AstraZeneca will continue to work with the FDA as it completes its review of the application," the company said in a statement on Friday. Shares in the company were down 1.8% in London trade.

In a separate decision the ODAC voted seven-to-one in favour of the company’s prostate cancer drug Truqap, or capivasertib, combined with abiraterone and androgen deprivation therapy.

Reporting by Frank Prenesti for Sharecast.com

See the latest RNS on Investegate

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Lloyds Bank is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.

Important legal information

Lloyds and Lloyds Bank are trading names of Halifax Share Dealing Limited. The Lloyds Bank Direct Investments Service is operated by Halifax Share Dealing Limited. Registered Office: Trinity Road, Halifax, West Yorkshire, HX1 2RG. Registered in England and Wales no. 3195646. Halifax Share Dealing Limited is authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN under registration number 183332. A Member of the London Stock Exchange and an HM Revenue & Customs Approved ISA Manager.

Logo Allfunds

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

FE fundinfo Logo

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

Refinitiv Logo

© 2026 Refinitiv, an LSEG business. All rights reserved.